Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.

Whether non-aspirin non-steroidal antiinflammatory drugs (NSAIDs) affect the risk of myocardial infarction is unclear. Also, it is unknown whether the effect varies by individual NSAIDs. To summarize the evidence from published observational studies on the risk of myocardial infarction associated with both traditional NSAIDs (tNSAIDs) and selective inhibitors of cyclooxygenase-2 (Coxibs), the authors conducted a systematic review of cohort and case-control studies on NSAIDs and myocardial infarction published between 2000 and 2005. Sixteen original studies were selected according to predefined criteria. Two researchers independently extracted the data on individual study characteristics and results. The authors calculated pooled relative risk (RR) estimates of myocardial infarction for specific NSAIDs compared with no NSAID use, tested the heterogeneity of effects, and evaluated potential reasons for heterogeneity. The pooled RR of myocardial infarction was 0.98 (95% confidence interval (CI): 0.92-1.05) for naproxen, 1.07 (95% CI: 1.02-1.12) for ibuprofen, 1.44 (95% CI: 1.32-1.56) for diclofenac, 0.96 (95% CI: 0.90-1.02) for celecoxib, and 1.26 (95% CI: 1.17-1.36) for rofecoxib (all doses). The pooled RR for rofecoxib at doses >25 mg/day was 1.78 (95% CI: 1.36-2.34), and 1.18 (95% CI: 1.07-1.31) for doses < or =25 mg/day. The RR associated with naproxen was 0.83 (95% CI: 0.72-0.90) among non-users of low-dose aspirin. The RR associated with rofecoxib (all doses) was 1.39 (95% CI: 1.25-1.54) among subjects without a history of myocardial infarction. The risk of myocardial infarction varies with individual NSAIDs. An increased risk was observed for diclofenac and rofecoxib, the latter one with a clear dose-response trend. There was a suggestion of a small increased risk with ibuprofen. Also, data suggest a small reduced risk for naproxen present only in non-users of aspirin, mainly people free of clinically apparent vascular disease.

[1]  K. Goldberg,et al.  Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. , 2004, Archives of internal medicine.

[2]  Sebastian Schneeweiss,et al.  Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.

[3]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[4]  R. Tarone,et al.  Risks of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs , 2005 .

[5]  J. Michael Gaziano,et al.  Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs , 2003, Circulation.

[6]  C Michael Stein,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.

[7]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial , 2004, The Lancet.

[8]  E. Rahme,et al.  Association between naproxen use and protection against acute myocardial infarction. , 2002, Archives of internal medicine.

[9]  W. Ray,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease☆ , 2003 .

[10]  C. Patrono,et al.  Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. , 2000, Epidemiology.

[11]  A. Maguire,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population , 2004, Circulation.

[12]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[13]  M. Reilly,et al.  The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. , 2004, Journal of the American College of Cardiology.

[14]  H. Sørensen,et al.  Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. , 2005, Archives of internal medicine.

[15]  T. Macdonald,et al.  Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.

[16]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[17]  Hershel Jick,et al.  Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. , 2002, British journal of clinical pharmacology.

[18]  C Michael Stein,et al.  Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study , 2002, The Lancet.

[19]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[20]  Daniel H Solomon,et al.  Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. , 2002, Archives of internal medicine.

[21]  G. FitzGerald,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[22]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[23]  S Greenland,et al.  Basic methods for sensitivity analysis of biases. , 1996, International journal of epidemiology.

[24]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[25]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[26]  Peter C Austin,et al.  Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. , 2003, Archives of internal medicine.

[27]  H. Guess,et al.  Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. , 2002, Archives of internal medicine.

[28]  G. FitzGerald.  Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.

[29]  Carol Coupland,et al.  Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.

[30]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[31]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[32]  W. White,et al.  Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. , 2002, The American journal of cardiology.

[33]  V. Fuster,et al.  Platelet-active drugs : the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[34]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[35]  P. Duke,et al.  Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.

[36]  Anthony Johnson,et al.  NSAIDs and Increased Blood Pressure , 1997, Drug safety.

[37]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[38]  R J Glynn,et al.  Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. , 1994, JAMA.

[39]  L. Hedges,et al.  The Handbook of Research Synthesis , 1995 .

[40]  C. Hennekens,et al.  An update on aspirin in the primary prevention of cardiovascular disease. , 2003, Archives of internal medicine.

[41]  M. Reilly,et al.  Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction , 2005, Annals of Internal Medicine.

[42]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[43]  W. Ray,et al.  Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study ☆ , 2002 .

[44]  James M Brophy,et al.  The Risk for Myocardial Infarction With Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults , 2005, Annals of internal medicine.

[45]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .